Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Bought by Massachusetts Wealth Management

Massachusetts Wealth Management grew its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 7.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,184 shares of the company’s stock after acquiring an additional 1,240 shares during the period. Massachusetts Wealth Management owned about 0.45% of Invesco Biotechnology & Genome ETF worth $1,270,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth about $26,000. GPS Wealth Strategies Group LLC bought a new position in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth about $30,000. UMB Bank n.a. bought a new stake in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at about $31,000. Covestor Ltd lifted its position in Invesco Biotechnology & Genome ETF by 24.2% in the 1st quarter. Covestor Ltd now owns 955 shares of the company’s stock valued at $62,000 after purchasing an additional 186 shares during the last quarter. Finally, Carnegie Investment Counsel bought a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $204,000.

Invesco Biotechnology & Genome ETF Trading Up 0.4 %

NYSEARCA:PBE traded up $0.30 during mid-day trading on Friday, hitting $67.57. The stock had a trading volume of 287 shares, compared to its average volume of 10,743. The stock has a market capitalization of $272.98 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. The company has a 50 day simple moving average of $69.97 and a 200-day simple moving average of $66.71. Invesco Biotechnology & Genome ETF has a 52 week low of $52.47 and a 52 week high of $72.72.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.